TY - JOUR
T1 - Association analysis of the tryptophan hydroxylase 2 gene polymorphisms in patients with methamphetamine dependence/psychosis
AU - Kobayashi, Hideaki
AU - Ujike, Hiroshi
AU - Iwata, Nakao
AU - Inada, Toshiya
AU - Yamada, Mitsuhiko
AU - Sekine, Yoshimoto
AU - Uchimura, Naohisa
AU - Iyo, Masaomi
AU - Ozaki, Norio
AU - Itokawa, Masanari
AU - Sora, Ichiro
PY - 2011
Y1 - 2011
N2 - There is a growing evidence that serotoninergic systems modulate dopaminergic neurotransmission. We analyzed the association between the variations in the brain tryptophan hydroxylase 2 (TPH2) gene, a rate limiting enzyme for serotonin biosynthesis, and methamphetamine (METH) dependence/psychosis in a Japanese population. We found ten single nucleotide polymorphisms (SNPs) and two polynucleotide polymorphisms in TPH2 gene exons and exon-intron boundaries. A total of 162 patients and 243 controls were used for the association analysis between these polymorphisms and METH dependence/psychosis. No significant differences were observed in either genotypic or allelic frequencies between METH dependent/psychotic patients and controls. A global test of differentiation among samples based on haplotype frequencies showed no significant association. With respect to latency of psychosis, prognosis of psychosis, and spontaneous relapse, we found no significant association with these SNPs. These results suggest that the TPH2 gene variants may not be a factor in vulnerability to METH dependence/psychosis.
AB - There is a growing evidence that serotoninergic systems modulate dopaminergic neurotransmission. We analyzed the association between the variations in the brain tryptophan hydroxylase 2 (TPH2) gene, a rate limiting enzyme for serotonin biosynthesis, and methamphetamine (METH) dependence/psychosis in a Japanese population. We found ten single nucleotide polymorphisms (SNPs) and two polynucleotide polymorphisms in TPH2 gene exons and exon-intron boundaries. A total of 162 patients and 243 controls were used for the association analysis between these polymorphisms and METH dependence/psychosis. No significant differences were observed in either genotypic or allelic frequencies between METH dependent/psychotic patients and controls. A global test of differentiation among samples based on haplotype frequencies showed no significant association. With respect to latency of psychosis, prognosis of psychosis, and spontaneous relapse, we found no significant association with these SNPs. These results suggest that the TPH2 gene variants may not be a factor in vulnerability to METH dependence/psychosis.
UR - http://www.scopus.com/inward/record.url?scp=79953063514&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953063514&partnerID=8YFLogxK
U2 - 10.2174/157015911795017335
DO - 10.2174/157015911795017335
M3 - Article
C2 - 21886586
AN - SCOPUS:79953063514
SN - 1570-159X
VL - 9
SP - 176
EP - 182
JO - Current Neuropharmacology
JF - Current Neuropharmacology
IS - 1
ER -